Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1910-1915

  Knudsen, Jenny Dahl ^a   Fuursted, Kurt ^a   Espersen, Frank ^a   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PERITONITIS; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030882025     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1910     Document Type: Article

References (22)

1. Bailey, E. M., M. J. Rybak, and G. W. Kaatz. 1991. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob. Agents Chemother. 35:1089-1092.
2. Cantú, T. G., N. A. Yamanaka-Yuen, and P. S. Lietman. 1994. Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. 18:533-543.
3. Caputo, G. M., P. C. Appelbauni, and H. H. Liu. 1993. Infections due to penicillin-resistant pneumococci. Arch. Intern. Med. 153:1301-1310.
4. Carper, H. T., G. W. Sullivan, and G. L. Mandell. 1987. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus. J. Antimicrob. Chemother. 19:659-662.
5. Chambers, H. F., and S. Kennedy. 1990. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob. Agents Chemother. 34:510-514.
6. Craig, W., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkens, Baltimore, Md.
7. den Hollander, J. G., J. D. Knudsen, J. W. Mouton, K. Fuursted, N. Frimodt-Møller, H. A. Verbrugh, and Espersen, F. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Submitted for publication.
8. Duffull, S. B., E. J. Begg, S. T. Chambers, and M. L. Barclay. 1994. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob. Agents Chemother. 38:2480-2482.
9. Dykhuizen, R. S., G. Harvey, N. Stephenson, D. Nathwani, and I. M. Gould. 1995. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob. Agents Chemother. 39:1842-1847.
10. Goldstein, F. W., P. Geslin, J. F. Acar, and the French Study Group. 1994. Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 13:33-34.
11. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28:143-160.
12. James, J. K., S. M. Palmer, D. P. Levine, and M. J. Rybak. 1996. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob. Agents Chemother. 40:696-700.
13. Klugman, K. P. 1990. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:171-196.
14. Knudsen. J. D., N. Frimodt-Møller, and F. Espersen. 1995. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob. Agents Chemother. 39:1253-1258.
15. Marrie, T. J. 1994. Community-acquired pneumonia. Clin. Infect. Dis. 18: 501-515.
16. Martínez, F., F. Martín-Luengo, A. García, and M. Valdés. 1994. Treatment of experimental endocarditis caused by penicillin-resistant Streptococcus sanguis with different doses of teicoplanin. Methods Find. Exp. Clin. Pharmacol. 16:247-251.
17. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed., vol. 13, no. 25. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Pallanza, R., M. Berti, B. P. Goldstein, E. Mapelli, E. Randisi, R. Scotti, and V. Arioli. 1983. Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics. J. Antimicrob. Chemother. 11:419-425.
19. Peetermans, W. E., J. J. Hoogeterp, A.-M. Hazekamp-van Dokkum, P. van den Broek, and H. Mattie. 1990. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob. Agents Chemother. 34:1869-1874.
20. Torney, H. L., F. J. Balistreri, M. T. Kenny, and W. D. Cheng. 1991. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus. J. Antimicrob. Chemother. 28:261-269.
21. Watanakunakorn, C., A. Greifenstein, K. Stroh, D. G. Jarjoura, D. Blend, A. Cugino, and A. J. Ognibene. 1993. Pneumococcal bacteremia in three community teaching hospitals from 1980-1989. Chest 103:1152-1156.
22. Wilson, A. P. R., R. N. Grüneberg, and H. Neu. 1994. A critical review of the dosage of teicoplanin in Europe and the USA. Int. J. Antimicrob. Agents 4(Suppl. 1):S1-S30.